Riskpilot← Back to searchSign inGet full accessEJP PHARMACEUTICAL ApS
APSActiveCVR 87923614Skodsborgparken 14, 3. thActivities of holding companies · NACE 6421Est. 19821 employees
Revenue 2025
DKK -28K
-14% vs 2024
EBITDA margin
100.0%
+14% vs 2024
Equity ratio
90.9%
Financial strength
Net profit 2025
DKK 214K
-48% vs 2024
| Revenue | DKK -28K | -14% |
| EBITDA | DKK -28K | +14% |
| Net profit | DKK 214K | -48% |
| Total assets | DKK 896K | -80% |
| Equity | DKK 814K | -82% |
| Employees | 1 | — |
Legal name
EJP PHARMACEUTICAL ApS
CVR number
87923614
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
18. februar 1982
Share capital
DKK 200.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene
Company purpose
Selskabets formål er fabrikation, handel og investering, herunder at erhverve og besidde aktier eller anparter i andre produktions- og handelsselskaber, samt at eje og drive landbrug.
Address
Skodsborgparken 14, 3. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -648 | -395 | -221 | -161 | -124 | -67 | — | — | -75 | -40 | -49 | -34 | -33 | -28 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -648 | -395 | -221 | -161 | -212 | -67 | -60 | -51 | -75 | -40 | -49 | -34 | -33 | -28 |
| Depreciation & amort. | -13 | -76 | -76 | -76 | -229 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -661 | -471 | -298 | -238 | -441 | -67 | -60 | -51 | -75 | -40 | -49 | -34 | -33 | -28 |
| Net financials | 3.471 | 1.838 | 1.151 | 2.276 | -1.542 | 1.736 | -800 | 774 | -50 | 621 | -528 | 561 | 437 | 261 |
| Profit before tax | 2.811 | 1.367 | 853 | 2.038 | -1.983 | 1.669 | -861 | 723 | -125 | 581 | -578 | 527 | 404 | 233 |
| Tax | 251 | 159 | 211 | 478 | -398 | 352 | -175 | 157 | 15 | 138 | -100 | 73 | -10 | 19 |
| Net profit | 2.559 | 1.208 | 642 | 1.560 | -1.585 | 1.317 | -685 | 566 | -140 | 443 | -478 | 454 | 414 | 214 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 27.346 | 8.530 | 8.861 | 10.677 | 8.693 | 7.973 | 7.183 | 7.606 | 6.967 | 7.418 | 6.765 | 4.195 | 4.513 | 896 |
| Equity | 27.245 | 8.453 | 8.595 | 10.155 | 8.570 | 7.887 | 7.127 | 7.585 | 6.946 | 7.275 | 6.683 | 4.137 | 4.429 | 814 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 102 | 77 | 231 | 491 | 123 | 86 | 56 | 21 | 22 | 143 | 82 | 58 | 84 | 81 |
| Total debt | 102 | 77 | 231 | 491 | 123 | 86 | 56 | 21 | 22 | 143 | 82 | 58 | 84 | 81 |
EBITDA margin
-2826600.0%
This company
15.8%
Market median
-17889973% vs market
20122025
Equity ratio
90.9%
This company
38.2%
Market median
+138% vs market
20122025
Return on equity
26.3%
This company
18.4%
Market median
+43% vs market
20122025
Net profit margin
21428200.0%
This company
8.1%
Market median
+264545579% vs market
20122025
Asset turnover
-0.03×
This company
1.12×
Market median
-103% vs market
20122025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 1995 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EJP PHARMACEUTICAL ApS 
HALICARE ApSBoard members of EJP PHARMACEUTICAL ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|